Nuwellis (NUWE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Executive summary
The annual meeting is scheduled for April 28, 2026, as a virtual event, with stockholders able to vote and participate online.
Two main proposals are up for vote: election of two Class I directors and ratification of Baker Tilly as the independent auditor for 2026.
Only holders of common stock as of March 24, 2026, are eligible to vote.
The Board recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal 1: Elect two Class I directors (Martin Emerson and David McDonald) for three-year terms expiring in 2029.
Proposal 2: Ratify Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2026.
No other shareholder proposals or nominations were received for this meeting.
Voting can be done online, by phone, or by mail, and proxies can be revoked before the meeting.
Board of directors and corporate governance
The Board consists of five directors divided into three staggered classes.
Majority of directors are independent per Nasdaq rules; all committee members are independent.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and responsibilities.
Annual performance evaluations and succession planning are conducted.
Directors are expected to attend all meetings, and the Board met 16 times in 2025.
Latest events from Nuwellis
- Updated share count, board changes, and voting details for the April 2026 Annual Meeting.NUWE
Proxy filing6 Apr 2026 - Q4 revenue and margin gains, strategic moves, and new leadership set up 2026 growth.NUWE
Q4 202520 Mar 2026 - Innovative fluid management platform targets $4.2B market with strong clinical and financial momentum.NUWE
Investor presentation10 Mar 2026 - Registering 4.28M shares for resale, proceeds from warrant exercises support working capital.NUWE
Registration Filing4 Feb 2026 - Q2 revenue up 6% to $2.2M, gross margin 67.2%, but cash runway and losses remain concerns.NUWE
Q2 20241 Feb 2026 - Q3 net income reached $2.4M, with improved margins and major reimbursement gains set for 2025.NUWE
Q3 202415 Jan 2026 - Improved margins and CMS reimbursement set stage for outpatient growth despite lower Q4 revenue.NUWE
Q4 202425 Dec 2025 - Flexible $25M shelf offering targets R&D and growth in fluid management devices.NUWE
Registration Filing16 Dec 2025 - Proxy seeks approval for director elections, reverse split, and auditor ratification to ensure compliance.NUWE
Proxy Filing2 Dec 2025